A survey of prescribing practices in the treatment of depression

Timothy Petersen, Christina Dording, Nicole B. Neault, Rebecca Kornbluh, Jonathan E. Alpert, Andrew A. Nierenberg, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: With the increasing number and type of antidepressants available to clinicians, there is a need to better understand current prescribing practices and to what degree these practices reflect research findings. The purpose of this study was to examine prescribing practices in a sample of psychiatrists attending a psychopharmacology review course and compare these results with empirical evidence. Method: 439 of 800 clinicians asked (55%) responded to a 10-item questionnaire that was given prior to beginning the review course. Items covered three major content areas: first-line preferences in the treatment of depression, antidepressant agents most associated with certain side effects, and first-line preferences in the treatment of certain depressive subtypes. Results: 214 (49%) clinicians indicated a belief that one antidepressant type is more efficacious than others. Of these 214 clinicians, 103 (48%) indicated selective serotonin reuptake inhibitors (SSRIs) as being most efficacious, while 53 (25%) indicated venlafaxine as being most efficacious; 378 (93%) clinicians indicated SSRIs as their first-line treatment preference. Mirtazapine (56%) was endorsed as most likely to be associated with weight gain, fluoxetine (57%) with sexual dysfunction, paroxetine (48%) with a discontinuation syndrome, and fluoxetine (52%) with agitation. For the treatment of anxious, atypical, and melancholic depression, SSRIs were the first choice of treatment (58%, 57%, and 57%), and for depression with prominent insomnia, mirtazapine and nefazadone (31% and 27%) were the first choices of treatment. Conclusions: Despite the lack of evidence of a significant difference in efficacy between older and newer agents, clinicians perceive the newer agents to be more efficacious than the older drugs [tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)] even in the melancholic and anxious depressive subtypes. Similarly, although sexual dysfunction and agitation appear to occur at similar rates with all the SSRIs, fluoxetine was perceived to be most likely to cause these side effects. These findings are significant as they highlight the discrepancy between empirical evidence and clinical practices and suggest that other factors influence clinicians' medication choices in the treatment of depression.

Original languageEnglish (US)
Pages (from-to)177-187
Number of pages11
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume26
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Depression
Serotonin Uptake Inhibitors
Fluoxetine
Antidepressive Agents
Therapeutics
Psychopharmacology
Paroxetine
Monoamine Oxidase Inhibitors
Tricyclic Antidepressive Agents
Sleep Initiation and Maintenance Disorders
Surveys and Questionnaires
Weight Gain
Psychiatry
Research
mirtazapine

Keywords

  • Antidepressants
  • Prescribing practices
  • Survey

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

A survey of prescribing practices in the treatment of depression. / Petersen, Timothy; Dording, Christina; Neault, Nicole B.; Kornbluh, Rebecca; Alpert, Jonathan E.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 26, No. 1, 2002, p. 177-187.

Research output: Contribution to journalArticle

Petersen, T, Dording, C, Neault, NB, Kornbluh, R, Alpert, JE, Nierenberg, AA, Rosenbaum, JF & Fava, M 2002, 'A survey of prescribing practices in the treatment of depression', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 26, no. 1, pp. 177-187. https://doi.org/10.1016/S0278-5846(01)00250-0
Petersen, Timothy ; Dording, Christina ; Neault, Nicole B. ; Kornbluh, Rebecca ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / A survey of prescribing practices in the treatment of depression. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2002 ; Vol. 26, No. 1. pp. 177-187.
@article{21e4c04d3ff14344886cbfce9024d8a5,
title = "A survey of prescribing practices in the treatment of depression",
abstract = "Background: With the increasing number and type of antidepressants available to clinicians, there is a need to better understand current prescribing practices and to what degree these practices reflect research findings. The purpose of this study was to examine prescribing practices in a sample of psychiatrists attending a psychopharmacology review course and compare these results with empirical evidence. Method: 439 of 800 clinicians asked (55{\%}) responded to a 10-item questionnaire that was given prior to beginning the review course. Items covered three major content areas: first-line preferences in the treatment of depression, antidepressant agents most associated with certain side effects, and first-line preferences in the treatment of certain depressive subtypes. Results: 214 (49{\%}) clinicians indicated a belief that one antidepressant type is more efficacious than others. Of these 214 clinicians, 103 (48{\%}) indicated selective serotonin reuptake inhibitors (SSRIs) as being most efficacious, while 53 (25{\%}) indicated venlafaxine as being most efficacious; 378 (93{\%}) clinicians indicated SSRIs as their first-line treatment preference. Mirtazapine (56{\%}) was endorsed as most likely to be associated with weight gain, fluoxetine (57{\%}) with sexual dysfunction, paroxetine (48{\%}) with a discontinuation syndrome, and fluoxetine (52{\%}) with agitation. For the treatment of anxious, atypical, and melancholic depression, SSRIs were the first choice of treatment (58{\%}, 57{\%}, and 57{\%}), and for depression with prominent insomnia, mirtazapine and nefazadone (31{\%} and 27{\%}) were the first choices of treatment. Conclusions: Despite the lack of evidence of a significant difference in efficacy between older and newer agents, clinicians perceive the newer agents to be more efficacious than the older drugs [tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)] even in the melancholic and anxious depressive subtypes. Similarly, although sexual dysfunction and agitation appear to occur at similar rates with all the SSRIs, fluoxetine was perceived to be most likely to cause these side effects. These findings are significant as they highlight the discrepancy between empirical evidence and clinical practices and suggest that other factors influence clinicians' medication choices in the treatment of depression.",
keywords = "Antidepressants, Prescribing practices, Survey",
author = "Timothy Petersen and Christina Dording and Neault, {Nicole B.} and Rebecca Kornbluh and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "2002",
doi = "10.1016/S0278-5846(01)00250-0",
language = "English (US)",
volume = "26",
pages = "177--187",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A survey of prescribing practices in the treatment of depression

AU - Petersen, Timothy

AU - Dording, Christina

AU - Neault, Nicole B.

AU - Kornbluh, Rebecca

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 2002

Y1 - 2002

N2 - Background: With the increasing number and type of antidepressants available to clinicians, there is a need to better understand current prescribing practices and to what degree these practices reflect research findings. The purpose of this study was to examine prescribing practices in a sample of psychiatrists attending a psychopharmacology review course and compare these results with empirical evidence. Method: 439 of 800 clinicians asked (55%) responded to a 10-item questionnaire that was given prior to beginning the review course. Items covered three major content areas: first-line preferences in the treatment of depression, antidepressant agents most associated with certain side effects, and first-line preferences in the treatment of certain depressive subtypes. Results: 214 (49%) clinicians indicated a belief that one antidepressant type is more efficacious than others. Of these 214 clinicians, 103 (48%) indicated selective serotonin reuptake inhibitors (SSRIs) as being most efficacious, while 53 (25%) indicated venlafaxine as being most efficacious; 378 (93%) clinicians indicated SSRIs as their first-line treatment preference. Mirtazapine (56%) was endorsed as most likely to be associated with weight gain, fluoxetine (57%) with sexual dysfunction, paroxetine (48%) with a discontinuation syndrome, and fluoxetine (52%) with agitation. For the treatment of anxious, atypical, and melancholic depression, SSRIs were the first choice of treatment (58%, 57%, and 57%), and for depression with prominent insomnia, mirtazapine and nefazadone (31% and 27%) were the first choices of treatment. Conclusions: Despite the lack of evidence of a significant difference in efficacy between older and newer agents, clinicians perceive the newer agents to be more efficacious than the older drugs [tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)] even in the melancholic and anxious depressive subtypes. Similarly, although sexual dysfunction and agitation appear to occur at similar rates with all the SSRIs, fluoxetine was perceived to be most likely to cause these side effects. These findings are significant as they highlight the discrepancy between empirical evidence and clinical practices and suggest that other factors influence clinicians' medication choices in the treatment of depression.

AB - Background: With the increasing number and type of antidepressants available to clinicians, there is a need to better understand current prescribing practices and to what degree these practices reflect research findings. The purpose of this study was to examine prescribing practices in a sample of psychiatrists attending a psychopharmacology review course and compare these results with empirical evidence. Method: 439 of 800 clinicians asked (55%) responded to a 10-item questionnaire that was given prior to beginning the review course. Items covered three major content areas: first-line preferences in the treatment of depression, antidepressant agents most associated with certain side effects, and first-line preferences in the treatment of certain depressive subtypes. Results: 214 (49%) clinicians indicated a belief that one antidepressant type is more efficacious than others. Of these 214 clinicians, 103 (48%) indicated selective serotonin reuptake inhibitors (SSRIs) as being most efficacious, while 53 (25%) indicated venlafaxine as being most efficacious; 378 (93%) clinicians indicated SSRIs as their first-line treatment preference. Mirtazapine (56%) was endorsed as most likely to be associated with weight gain, fluoxetine (57%) with sexual dysfunction, paroxetine (48%) with a discontinuation syndrome, and fluoxetine (52%) with agitation. For the treatment of anxious, atypical, and melancholic depression, SSRIs were the first choice of treatment (58%, 57%, and 57%), and for depression with prominent insomnia, mirtazapine and nefazadone (31% and 27%) were the first choices of treatment. Conclusions: Despite the lack of evidence of a significant difference in efficacy between older and newer agents, clinicians perceive the newer agents to be more efficacious than the older drugs [tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)] even in the melancholic and anxious depressive subtypes. Similarly, although sexual dysfunction and agitation appear to occur at similar rates with all the SSRIs, fluoxetine was perceived to be most likely to cause these side effects. These findings are significant as they highlight the discrepancy between empirical evidence and clinical practices and suggest that other factors influence clinicians' medication choices in the treatment of depression.

KW - Antidepressants

KW - Prescribing practices

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=0036139897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036139897&partnerID=8YFLogxK

U2 - 10.1016/S0278-5846(01)00250-0

DO - 10.1016/S0278-5846(01)00250-0

M3 - Article

VL - 26

SP - 177

EP - 187

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -